Graphite Bio Inc

GRPH 4 | $3.27 1.84% 490K

(0.0% 1d) (0.0% 1m) (12.8% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

gene therapies

add to watch list Paper trade email alert is off

Acumen Pharmaceuticals Inc

ABOS | $3.17 0.32% 0.32% 150K

Professional, Scientific, and T...

(0.0% 1d) (-25.6% 1m) (-13.7% 1y) (0.0% 2d) (1.0% 3d) (0.3% 7d) (-43.49% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 190,452,896
https://www.acumenpharm.com
Sec Filling | Patents | 2021 employees

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Aerovate Therapeutics Inc

AVTE M | $21.27 -8.4% -9.17% 300K

Professional, Scientific, and T...

(0.0% 1d) (-13.8% 1m) (23.7% 1y) (0.0% 2d) (4.7% 3d) (5.3% 7d) (105.25% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 592,582,200
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

treatment

add to watch list Paper trade email alert is off

Elevation Oncology Inc

ELEV | $3.89 -9.95% -11.05% 660K

Professional, Scientific, and T...

(0.0% 1d) (-5.7% 1m) (152.6% 1y) (0.0% 2d) (6.7% 3d) (7.7% 7d) (100.99% volume)
Earnings Calendar: 2022-11-04
Market Cap: $ 189,252,837
https://elevationoncology.com
Sec Filling | Patents | 8 employees

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. The company makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with its peers Elevation Oncology works towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at www.NRG1fusion.com.

treatment cancer

add to watch list Paper trade email alert is off

Mister Car Wash Inc

MCW 4 | $6.95 -1.14% 0.0% 2.4M

Professional, Scientific, and T...

(0.0% 1d) (-5.0% 1m) (-16.7% 1y) (0.0% 2d) (2.8% 3d) (4.8% 7d) (52.29% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 2,208,953,820
https://mistercarwash.com
Sec Filling | Patents | 4625 employees

Headquartered in Tucson, Arizona, Mister Car Wash operates over 340 car washes nationwide. The Mister Car Wash brand is anchored in quality, friendliness and a commitment to creating memorable customer experiences. Mister Car Wash’s people are what make it successful and allow it to achieve these high standards. Mister Car Wash continues to focus on recruiting and retaining top talent, developing best-in-class training programs and investing in employee benefits to cultivate a positive company culture.

brands

add to watch list Paper trade email alert is off

Beauty Health Company (The) - Class A

SKIN | $3.14 -2.48% -2.55% 1.2M

Professional, Scientific, and T...

(0.0% 1d) (-21.7% 1m) (-72.5% 1y) (0.0% 2d) (-1.5% 3d) (-1.5% 7d) (7.92% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 387,662,274
https://www.beautyhealth.com/
Sec Filling | Patents | n/a employees

BeautyHealth is a category-creating beauty health company focused on bringing innovative products to market. Its flagship brand, HydraFacial, is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. Leading the charge in beauty health as a category-creator, HydraFacial uses a unique delivery system to cleanse, extract, and hydrate with their patented hydradermabrasion technology and super serums that are made with nourishing ingredients, providing an immediate outcome and creating an instantly gratifying glow in just three steps and 30 minutes. HydraFacial® and Perk™ products are available in over 87 countries with over 16,000 delivery systems globally and millions of treatments performed each year.

brands msa skin treatment 3d

add to watch list Paper trade email alert is off